Navigation Links
Pharmasset Initiates Phase 2b Clinical Trial of PSI-7977 for Chronic Hepatitis C Genotypes 1, 2, and 3
Date:8/24/2010

has recently initiated 12 weeks of dosing in a Phase 2b study, and PSI-938, an unpartnered guanosine nucleotide analog in a Phase 1 study. We also have in our pipeline an additional purine nucleotide analog, PSI-661, in advanced preclinical development. Racivir, for the treatment of HIV, has completed a Phase 2 clinical study.

Pegasys® and Copegus® are registered trademarks of Roche.ContactRichard E. T. Smith, Ph.D. VP, Investor Relations and Corporate Communicationsrichard.smith@pharmasset.comOffice: +1 (609) 613-4181Forward-Looking StatementsPharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:  Statements in this press release that are not historical facts are "forward-looking statements," including, without limitation, statements  that involve risks, uncertainties, and other important factors, including, without limitation,  the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates,  the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized.  For a discussion of risks, uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2009 and our Quarterly Reports on Form 10-Q for the periods ended December 31, 2009, March 31, 2010 and June 30, 2010 filed with the Securities and Exchange Commission and disc
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 PuraMed BioScience®, Inc., (OTC Pink: ... medicinal and healthcare products, announced it received the initial ... hemp-based, advanced headache relief product, for planned distribution to ... Colorado , Washington State , ... the MigraPure H Advanced headache relief gel formulation completed, ...
(Date:12/24/2014)... -- ResMed (NYSE: RMD ) today announced its ... device manufacturer BMC Medical Co., Ltd. The ... below infringe ResMed,s patents, and entered an order prohibiting BMC ... the United States : , iVolve nasal ... nasal pillows mask , iVolve full face mask ...
(Date:12/24/2014)... MASON, Ohio , Dec. 23, 2014 /PRNewswire/ ... industry-leading treatment decision support to healthcare providers for ... that it has secured $30 million in equity ... Virginia C. Drosos , President and Chief ... increased clinical adoption and development of Assurex Health,s ...
Breaking Medicine Technology:PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... SANTA CLARA, Calif., Aug. 15, 2011 NewCardio, Inc., (OTC ... results for the second quarter ended June 30, 2011. More ... Quarterly Report on Form 10-Q, filed today with the Securities ... QTinno® was selected by a top 5 global pharmaceutical company ...
... Aug. 15, 2011 Millennium HealthCare ... KBL, LLP, a Public Company Accounting Oversight Board (PCAOB) ... KBL, LLP provides a combination of ... emerging businesses. Their professionals maintain an entrepreneurial spirit and ...
Cached Medicine Technology:NewCardio Announces Financial Results for Its 2011 Second Quarter 2NewCardio Announces Financial Results for Its 2011 Second Quarter 3NewCardio Announces Financial Results for Its 2011 Second Quarter 4NewCardio Announces Financial Results for Its 2011 Second Quarter 5NewCardio Announces Financial Results for Its 2011 Second Quarter 6NewCardio Announces Financial Results for Its 2011 Second Quarter 7NewCardio Announces Financial Results for Its 2011 Second Quarter 8Millennium HealthCare Inc. Engages KBL, LLP 2
(Date:12/24/2014)... 2014 For chic ladies, new fashionable outfits ... part of their Holiday Wish List, Angeldress.co.uk has ... ways to accent ladies’ holiday wardrobe by launching a promotion ... all over the discount of 80% off, like a cheap ... ship. The company’s chic wedding dresses are among the hottest ...
(Date:12/24/2014)... 2014 The report offers details on ... various market dynamics such as the key trends, the ... wait time for U.S. sports medicine, the impact of ... the challenges faced by the market. , Browse report ... The report also provides an overview of the global ...
(Date:12/24/2014)... 24, 2014 Dental implants benefit millions ... tooth replacement. They offer the strongest and most secure ... other forms of tooth replacement. They will never slip ... adjacent teeth for support, and they prevent the jaw ... told that they are not suitable candidates for dental ...
(Date:12/24/2014)... Final Cut Pro X plugin ... Film Studios. , “The ProDenoise plugin that allows users to ... said Christina Austin, CEO of Pixel Film Studios. “ProDenoise is ... X editors toolbox.” , Final Cut Pro X users can ... footage with ProDenoise from Pixel Film Studios. ProDenoise can quickly ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 ... vaccine that U.S. officials are preparing to test in West ... vaccine produced a safe and potent immune response in Africans. ... more than 100 Ugandans in 2009 and 2010, prompted the ... protect a person against infection by Ebola, said study author ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Starts Its Big Sales by Offering Various Kinds of Cheap Clothes and Fashion Accessories 2Health News:Sports Medicine Market Report 2014: Global Industry Analysis, Share, Size, Trends, Growth and Forecast report 2Health News:Innovative Dental Implant Procedure to Gain Momentum in the New Year 2Health News:Pixel Film Studios released the ProDenoise plugin for Final Cut Pro X today. 2Health News:Early Study Offers Hope for an Ebola Vaccine 2Health News:Early Study Offers Hope for an Ebola Vaccine 3Health News:Early Study Offers Hope for an Ebola Vaccine 4
... new study shows exercise may allow for better brain ... mentally engaged.// ,Researchers from the Oregon Health and ... causes physical changes in the brain. Researchers say they ... want environmental factors such as smoking, drinking, and obesity ...
... new study shows a novel new drug is beneficial ... cells and is the first in a new class ... ,The drug is called cytotoxic T-lymphocyte-associated antigen 4-IgG1 or ... the treatment of rheumatoid arthritis. Researchers from Belgium conducted ...
... shows bone marrow stem cells may help restore damaged ... the American Heart //Association’s Scientific Sessions 2003 presented their ... that took place in 2001. Results from that trial ... his own bone marrow had improved heart function. ...
... say women will now have to talk seriously with their ... ,Pancreatic cancer affects only 31,000 Americans a year, but it ... study of 88,000 nurses found that those who took two ... had a 58 percent higher risk of pancreatic cancer.,Researchers expected ...
... A new study shows the symptoms women experience before ... the symptoms they expect to experience. ,Researchers interviewed ... and were discharged from five different medical sites. The ... asked the women to identify their symptoms before their ...
... new study shows children who are obese are more ... not overweight. ,Researchers from the University of Michigan studied ... The children and their parents took part in the ... weight, behavior, physical and mental health, education, demographic, and ...
Cached Medicine News:Health News:Aspirin usage linked with pancreatic cancer 2
... to match the pace and unique needs ... on Philips strong heritage in patient monitoring, ... has highly flexible screen configuration; an extensive ... such as Event Surveillance, EASI derived 12-lead ...
... is a comprehensive vital sign monitor. , ,Adult, ... products for efficiency in patient care., ,Standard Functions: ... - Temp - Multi-gas Sensor (HAL, ENF, ISO, ... ,Optional Functions: ,5-Lead ECG - FiO 2 - ...
... CS makes the outstanding ... CS even more flexible. ... Technologies, the Wireless Propaq ... ethernet Local Area Networks ...
... The Acuity Central Monitoring Station ... for up to 60 patients from ... interface uses simple point and click ... trackball. The clinician can initiate or ...
Medicine Products: